Lumida
/ALDX
⌘K
Aldeyra Therapeutics Inc

Aldeyra Therapeutics Inc

ALDX
$1.52USD+0.00%+0.00 today

MARKET CAP

91.7M

P/E (TTM)

FWD P/E

DAY RANGE

$1 – $2

52W RANGE

$1
$6

AI Summary

Stalk
StalkMedium

ALDX remains in an early/fragile Stage 1 consolidation base with accumulation signals from follow-through and exhaustion tags. Medium-term bias is bullish given the flattening 9/21 EMA regime and bottoming patterns, but price recently extended into resistance and is now pulling back. Short-term timing is neutral, so execution is deferred—stalking for pullbacks into the 9/21 EMA support zone.

  • Phase 3 Reproxilab reduced ocular discomfort (p=0.002), outperforming slow-acting rivals
  • Cash reserves >$100M support clinical programs into 2027 without dilutive financing
  • FY22 net loss of $62M increases funding risk as R&D expenses rise
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICTREND
Sales, Adj.
YoY %
P / Sales
EV / Sales
Gross Profit, Adj.
YoY %
Margin %
EV / Gross Profit
EBITDA, Adj.
YoY %
Margin %
EV / EBITDA
EBIT
YoY %
Margin %
EV / EBIT
Net Income
YoY %
Net Margin
EPS (GAAP)
YoY %